High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study

Bone Marrow Transplantation

Volumn 26, Issue 10, 2000, Pages 1045-1049

  Meloni, G ^a   Capria, S ^a   Trasarti, S ^a   Ferrazza, G ^a   Micozzi, A ^a   Petrucci, M T ^a   Simone, F ^a   Trisolini, S M ^a   Mandelli, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autologous stem cell transplantation; High dose idarubicine; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; BUSULFAN; CD34 ANTIGEN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; NARCOTIC ANALGESIC AGENT; PARAPROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ANOREXIA; ARTICLE; AUTOTRANSPLANTATION; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANCE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUTH MUCOSA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASIA; PERIPHERAL BLOOD STEM CELL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033677352     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702668     Document Type: Article

References (30)

1. Plasma cell myeloma: New biological insights and advances in therapy
2. The treatment of multiple myeloma
3. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?
4. Combination chemotherapy versus melphalan prednisone in the treatment of multiple myeloma: An overview of published trials
5. High-risk multiple myeloma treated with high-dose melphalan
6. High-dose melphalan for multiple myeloma: Long-term follow-up data
7. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma
8. High dose melphalan and autologous bone marrow transplantation for high risk myeloma
9. Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors
10. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma
11. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
12. Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma
13. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French registry on autologous transplantation in multiple myeloma
14. High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of phase II trial involving 63 patients
15. Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
16. High-dose therapy refractory multiple myeloma: Improved prognosis with better supportive care and double transplants
17. Third autologous stem cell transplants for late relapse of multiple myeloma
18. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
19. Idarubicin related side effects recipients of T-cell depleted allogeneic bone marrow transplants are schedule dependent
20. Prevention of leukemic relapse after transplantation with lymphocyte-depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracyclines
21. Intensification of the conditioning regimen for allogeneic bone marrow transplantation in recipients of T-cell depleted grafts by the addition of anthracyclines
22. Idarubicin to intensify the conditioning regimen of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission
23. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: An Italian multicenter study
24. Therapy induced Ph1 suppression in chronic myeloid leukemia: Molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion
25. Idarubicin, melphalan and cyclophosphamide: An intensified high-dose regimen for the treatment of myeloma patients
26. Treatment of multiple myeloma
27. Peripheral blood progenitor cell autologous transplantation in multiple myeloma
28. High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up front or rescue treatment? Results of a multicenter sequential randomized clinical trial
29. Single vs double transplant in myeloma: A randomised trial of the 'Inter Groupe Francais du Myelome' (IFM)